Cefuroxime

Chemical formula: C₁₆H₁₆N₄O₈S  Molecular mass: 424.385 g/mol  PubChem compound: 5479529

Therapeutic indications

Cefuroxime is indicated for:

Community acquired pneumonia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Community acquired pneumonia and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Soft-tissue infections, cellulitis, erysipelas, wound infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
at least one of
Soft tissue infection
Cellulitis
Local infection of wound
and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

Erysipelas

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Intra-abdominal infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Infectious disease of abdomen and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Urinary tract infectious disease and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Surgical prophylaxis for gastrointestinal, gynaecological and orthopaedic operations

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Preventive procedure and additionally at least one of
Operative procedure on digestive system
Obstetric operation
Operation on female genital organs
Operation on musculoskeletal system

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Surgical prophylaxis for cardiovascular and oesophageal operations

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Preventive procedure and additionally at least one of
Surgical procedure on cardiovascular system
Operation on esophagus

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Urinary tract, soft-tissue, intra-abdominal and wound infections

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
at least one of
Community acquired pneumonia
Soft tissue infection
Cellulitis
Local infection of wound
Urinary tract infectious disease
Infectious disease of abdomen
and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

Erysipelas

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute exacerbation of chronic bronchitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute exacerbation of chronic bronchitis and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute tonsillitis and pharyngitis, acute bacterial sinusitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Acute tonsillitis
Acute pharyngitis
Acute bacterial sinusitis
and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute otitis media

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute otitis media and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lyme disease

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Lyme disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Community acquired pneumonia

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Community acquired pneumonia and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lyme disease

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Lyme disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute tonsillitis and pharyngitis, acute bacterial sinusitis

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Acute tonsillitis
Acute pharyngitis
Acute bacterial sinusitis
and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute otitis media

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Acute otitis media and additionally at least one of
Cefuroxime susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cefuroxime is contraindicated in the following cases:

Hypersensitivity to cephalosporin antibiotics, history of hypersensitivity to penicillins, monobactams and carbapenems

at least one of
Cephalosporin allergy
Allergy to penicillin
Monobactam allergy
Carbapenem allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: ZINACEF Powder for injection / infusion
Summary of Product Characteristics (SPC) 2019: ZINNAT Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈